{"id":265,"date":"2026-11-03T02:54:13","date_gmt":"2026-11-03T02:54:13","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=265"},"modified":"2026-11-03T02:54:13","modified_gmt":"2026-11-03T02:54:13","slug":"s-14-a-brain-penetrant-covalent-butyrylcholinesterase-inhibitor-with-in-vivo-procognitive-efficacy-target-lead-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/s-14-a-brain-penetrant-covalent-butyrylcholinesterase-inhibitor-with-in-vivo-procognitive-efficacy-target-lead-intelligence-dossier\/","title":{"rendered":"(S)-(+)-14: A Brain-Penetrant Covalent Butyrylcholinesterase Inhibitor with In Vivo Procognitive Efficacy \u2014 Target &#038; Lead Intelligence Dossier"},"content":{"rendered":"<h2 class=\"wp-block-heading\">The problem: the other cholinesterase<\/h2>\n\n<p>In early Alzheimer&rsquo;s disease, acetylcholinesterase (AChE) does most of the work terminating cholinergic signaling. But as the disease advances, <strong>AChE activity falls while butyrylcholinesterase (BChE) rises<\/strong> &mdash; in late-stage AD, BChE becomes the dominant hydrolase controlling synaptic acetylcholine. That makes <strong>selective BChE inhibition<\/strong> an attractive, stage-appropriate strategy: raise ACh where it matters without the dose-limiting peripheral, parasympathomimetic toxicity that comes with hitting AChE.<\/p>\n\n<p>The catch: despite decades of BChE inhibitors, <strong>only one cymserine derivative (bisnorcymserine) has reached the clinic.<\/strong> The field needs new, selective, <em>brain-penetrant<\/em> chemotypes with demonstrated in vivo efficacy.<\/p>\n\n<h2 class=\"wp-block-heading\">The strategy: a selective carbamate warhead on a pyrrolidine scaffold<\/h2>\n\n<p>Gobec and co-workers (Ljubljana, with structural work from Brazzolotto\/Nachon) built a series of <strong>N-alkylpyrrolidine carbamates<\/strong> and optimized for three things at once: hBChE potency, selectivity over hAChE, and CNS exposure. Structure-guided SAR across the aryl carbamate and the pyrrolidine N-substituent converged on <strong>(S)-(+)-14<\/strong>, the (S)-enantiomer of an <strong>N-benzylpyrrolidine naphthyl-carbamate<\/strong>.<\/p>\n\n<h2 class=\"wp-block-heading\">The chemistry: building the enantiopure carbamate<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"505\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_scheme-1024x505.png\" alt=\"\" class=\"wp-image-261\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_scheme-1024x505.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_scheme-300x148.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_scheme-768x379.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_scheme-1536x757.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_scheme-2048x1010.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">A short, convergent route to (S)-(+)-14: Cbz-protect the pyrrolidine nitrogen, form the carbamate with 2-naphthyl isocyanate (DMAP), remove the Cbz by hydrogenolysis, then N-benzylate. Redrawn by Astinova Bio Labs (RDKit).<\/figcaption><\/figure>\n\n<p><strong>(S)-(+)-14<\/strong> is (S)-(1-benzylpyrrolidin-3-yl)methyl naphthalen-2-ylcarbamate (C<sub>23<\/sub>H<sub>24<\/sub>N<sub>2<\/sub>O<sub>2<\/sub>). The route is short and convergent: Cbz-protect the pyrrolidine nitrogen of enantiopure pyrrolidin-3-ylmethanol; form the carbamate with <strong>2-naphthyl isocyanate<\/strong> (DMAP); remove the Cbz by hydrogenolysis; and <strong>N-benzylate<\/strong> with benzyl bromide. The single stereocenter is carried through from a commercial enantiopure building block (98% ee).<\/p>\n\n<h2 class=\"wp-block-heading\">The mechanism: carbamoylation of the catalytic serine<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"464\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_mechanism-1024x464.png\" alt=\"\" class=\"wp-image-262\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_mechanism-1024x464.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_mechanism-300x136.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_mechanism-768x348.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_mechanism-1536x696.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_mechanism-2048x927.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">Covalent, pseudo-irreversible inhibition: the catalytic Ser198 attacks the carbamate, transferring the naphthyl-carbamoyl group onto the enzyme and releasing the N-benzylpyrrolidinyl-methanol leaving group. Slow decarbamoylation regenerates active BChE. Mechanism schematic by Astinova Bio Labs.<\/figcaption><\/figure>\n\n<p>Like rivastigmine, (S)-(+)-14 is a <strong>covalent, pseudo-irreversible<\/strong> inhibitor. The catalytic <strong>Ser198<\/strong> attacks the carbamate carbonyl, transferring the <strong>naphthyl-carbamoyl<\/strong> group onto the enzyme and releasing the <strong>(1-benzylpyrrolidin-3-yl)methanol<\/strong> leaving group. The carbamoyl-enzyme is catalytically dead and reactivates only slowly by decarbamoylation. Kinetically this shows up as <strong>time-dependent inhibition<\/strong> &mdash; IC<sub>50<\/sub> falls with preincubation &mdash; the signature of covalent engagement.<\/p>\n\n<p>Two numbers make the case: <strong>hBChE IC<sub>50<\/sub> = 30 nM<\/strong>, and <strong>hAChE IC<sub>50<\/sub> &gt; 100 &micro;M<\/strong> (no measurable AChE inhibition). That is the clean BChE selectivity the strategy demands.<\/p>\n\n<h2 class=\"wp-block-heading\">The structural proof: caught on Ser198<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"680\" height=\"867\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_binding_30gy.png\" alt=\"\" class=\"wp-image-263\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_binding_30gy.png 680w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/bche_binding_30gy-235x300.png 235w\" sizes=\"auto, (max-width: 680px) 100vw, 680px\" \/><figcaption class=\"wp-element-caption\">X-ray of the covalent complex (PDB pdb_000030gy): the naphthyl-carbamoyl group bonded to catalytic Ser198, triad Ser198&ndash;His438&ndash;Glu325 intact, and the released N-benzylpyrrolidinyl-methanol leaving group in the gorge. Rendered by Astinova Bio Labs (3Dmol.js).<\/figcaption><\/figure>\n\n<p>The X-ray structure of the enzyme&ndash;inhibitor complex (<strong>PDB pdb_000030gy<\/strong>) shows exactly what the kinetics imply: the <strong>naphthyl-carbamoyl group covalently bonded to Ser198<\/strong>, with the catalytic triad (Ser198&ndash;His438&ndash;Glu325) intact and the released N-benzylpyrrolidinyl-methanol leaving group still sitting in the active-site gorge. A companion structure of the non-reactive analogue <strong>compound 9<\/strong> (pdb_000030gx) captures the pre-reaction, non-covalent pose &mdash; together they bracket the reaction coordinate. The (S) configuration of the leaving-group alcohol modeled in the gorge rationalizes the enantiopreference.<\/p>\n\n<h2 class=\"wp-block-heading\">The in vivo payoff: procognitive, clean<\/h2>\n\n<ul class=\"wp-block-list\"><li><strong>Brain-penetrant.<\/strong> Predicted CNS+ in PAMPA-BBB (Papp ~314 nm\/s) and achieves brain exposure after intraperitoneal dosing in mice.<\/li><li><strong>Metabolically stable<\/strong> in human-hepatocyte assays &mdash; good enough to support in vivo work.<\/li><li><strong>Procognitive.<\/strong> As the L-tartrate salt (10 mg\/kg i.p.), it <strong>reverses scopolamine-induced cognitive impairment<\/strong> in mice across two paradigms &mdash; fear-conditioned <strong>passive avoidance<\/strong> and <strong>novel object recognition<\/strong> &mdash; <strong>without cholinergic adverse effects or motor deficits<\/strong>.<\/li><\/ul>\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n<ul class=\"wp-block-list\"><li><strong>A validated, stage-appropriate AD lead.<\/strong> A selective, brain-penetrant covalent BChE inhibitor with demonstrated procognitive efficacy and a solved co-crystal is exactly what a thin clinical pipeline needs.<\/li><li><strong>Selectivity by design, not luck.<\/strong> The carbamate warhead plus the N-benzylpyrrolidine scaffold delivers &gt;3,000-fold BChE\/AChE selectivity &mdash; the key to avoiding peripheral cholinergic toxicity.<\/li><li><strong>A clean covalent handle.<\/strong> A carbamate that carbamoylates Ser198 and decarbamoylates slowly gives durable, time-dependent inhibition that still reverses &mdash; a tunable middle ground between reversible and irreversible chemistry.<\/li><\/ul>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<p><strong>Reference:<\/strong> Mastnak-Sokolov, P.; Ko&scaron;ak, U.; Meden, A.; Knez, D.; &#381;akelj, S.; Horvat, S.; Pi&scaron;lar, A.; Kljun, J.; Igert, A.; Dias, J.; Nachon, F.; Brazzolotto, X.; Novak, M.; Rydlova, V.; Zdarova Karasova, J.; Soukup, O.; Manik, A.; Detka, J.; Sa&#322;at, K.; Gobec, S. &ldquo;Structure-Guided Design of a Brain-Penetrant Covalent Inhibitor of Human Butyrylcholinesterase with In Vivo Procognitive Efficacy.&rdquo; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>, <em>69<\/em>, 22506&ndash;22538. DOI: 10.1021\/acs.jmedchem.6c01737. Open access under CC-BY 4.0.<\/p>\n\n<p><em>All visuals are original to Astinova Bio Labs: the synthesis scheme and mechanism drawn with RDKit\/Matplotlib; the covalent-complex view rendered with 3Dmol.js from the deposited co-crystal PDB pdb_000030gy. No paper figures were reused.<\/em><\/p>\n\n<p><em>Astinova Bio Labs designs and makes molecules like these &mdash; covalent warhead and scaffold design, enantioselective synthesis, and structure-based binding analysis. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your target.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>A structure-guided, brain-penetrant covalent BChE inhibitor for late-stage Alzheimer&#8217;s: (S)-(+)-14 carbamoylates the catalytic Ser198 (hBChE IC50 30 nM, no AChE activity), is CNS+, and reverses scopolamine-induced cognitive deficits in mice with no cholinergic side effects \u2014 with a co-crystal to prove the mechanism.<\/p>\n","protected":false},"author":1,"featured_media":260,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[87,86,88,89,36,28,85,64,90],"class_list":["post-265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-alzheimers-disease","tag-butyrylcholinesterase","tag-carbamate","tag-cholinesterase","tag-cns-penetrant","tag-covalent-inhibitors","tag-neurodegeneration","tag-selectivity","tag-structure-based-design"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=265"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/265\/revisions"}],"predecessor-version":[{"id":266,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/265\/revisions\/266"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/260"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}